Compounds > ici 204,219
Page last updated: 2024-11-05

ici 204,219 and Cytokine Release Syndrome

ici 204,219 has been researched along with Cytokine Release Syndrome in 1 studies

zafirlukast: a leukotriene D4 receptor antagonist

Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Citron, F1
Perelli, L1
Deem, AK1
Genovese, G1
Viale, A1

Other Studies

1 other study available for ici 204,219 and Cytokine Release Syndrome

ArticleYear
Leukotrienes, a potential target for Covid-19.
    Prostaglandins, leukotrienes, and essential fatty acids, 2020, Volume: 161

    Topics: Acetates; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Betaco

2020